Two studies, which jointly included 420 patients with stage I Non-Small-Cell Lung Carcinoma (NSCLC), suggested that high EPHA2 expression was correlated with well-differentiated tumors, reduced smoking status, adenocarcinoma histological type, stage IA tumors, as well as the presence of Epidermal Growth Factor Receptor (EGFR) gene mutations. The gene discussed is EPHA2; the disease is non-small cell lung carcinoma.